TrialClinical and experimental medicine2024

The role of trimethoprim/sulfamethoxazole in preventing opportunistic infections in systemic lupus erythematosus patients receiving low-level immunosuppressive treatment: an open-label, randomized, controlled trial.

Paopat Munthananuchat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.